Most existing evaluations of cancer biomarkers are individually conducted using respective clinical trial data or simulations based on evidence from clinical trials (for instance, [2] for KRAS and BRAF in colorectal cancer, and [26] for EGFR in lung cancer). This evidence concerns the gene EGFR and colorectal cancer.